Free Trial

Tourmaline Bio Q2 2023 Earnings Report

Tourmaline Bio logo
$16.65 -0.08 (-0.48%)
As of 03/28/2025 04:00 PM Eastern

Tourmaline Bio EPS Results

Actual EPS
-$2.00
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Tourmaline Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tourmaline Bio Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Remove Ads

Tourmaline Bio Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
Tourmaline Bio (TRML) Gets a Buy from Wedbush
Tourmaline Bio price target raised to $43 from $42 at Wedbush
See More Tourmaline Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tourmaline Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tourmaline Bio and other key companies, straight to your email.

About Tourmaline Bio

Tourmaline Bio (NASDAQ:TRML) operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

View Tourmaline Bio Profile

More Earnings Resources from MarketBeat